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MLL fusions are leukemogenic transcription factors
that enhance transcriptional elongation through
modification of chromatin and RNA Pol II. Global
transcription rates and chromatin changes accom-
panying the transformation process induced by
MLL-ENL were monitored by nascent RNA-seq and
ChIP-seq, revealing 165 direct target genes sepa-
rated into two distinct clades. ME5 genes bound
MLL-ENL at the promoter, relied onDOT1L-mediated
histone methylation, and coded preferentially for
transcription factors, including many homeobox
genes. A distinct ME3 group accumulated MLL-ENL
beyond the termination site, was dependent on
P-TEFb-mediated phosphorylation of RNA Pol II for
transcription, and translated mainly into proteins
involved in RNA biology and ribosome assembly.
This dichotomy was reflected by a differential sensi-
tivity toward small molecule inhibitors, suggesting
the possibility of a combinatorial strategy for treat-
ment of MLL-induced leukemia.
INTRODUCTION
Mixed-lineage leukemia (MLL) with translocations creating MLL
fusions is one of the most aggressive hematopoietic cancers
known. Prognosis is particularly dismal in pediatric leukemia,
which frequently carries this genetic aberration, with 5-year
survival rates hovering around 40% (Pieters et al., 2007). Under-
scoring the extraordinary transforming power of MLL fusion pro-
teins, it has been shown that MLL cells carry one of the lowest
rates of secondary mutations ever detected in human cancers
(Andersson et al., 2015).
The more frequently occurring fusions that juxtapose MLL to
members of either the ENL/AF9 or the AFF1–4 families use an
unusual mechanism of transcriptional activation that targets
the elongation step of transcription (for a review, see Slany,
2010). These particular fusion partners are members of the
EAP (elongation assisting protein) multiprotein complex that310 Cell Reports 15, 310–322, April 12, 2016 ª2016 The Authors
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Mueller et al., 2007, 2009). The hallmark of this complex is
the presence of P-TEFb (positive transcription elongation
complex b), a dimer of CDK9 and CyclinT1 or T2. Substrate for
P-TEFb is the second serine within the C-terminal repeat domain
of RNA polymerase II (RNA Pol II) that has to be phosphorylated
for an elongation-competent enzyme. In addition, P-TEFb phos-
phorylates proteins like NELF (negative elongation factor) that
induce RNA Pol II to pause after transcriptional initiation. Thus,
MLL fusion proteins specifically stimulate transcriptional elonga-
tion, which is the rate-limiting process during transcription of
many genes associated with differentiation, proliferation, and
rapid response to external stimuli (Jonkers and Lis, 2015).
Besides, many MLL fusion partners bind either directly or
through intermediary proteins to the histone methyltransferase
DOT1L. DOT1L is the only known enzyme that catalyzes methyl-
ation of H3K79, and this modification, especially dimethylation
and trimethylation, has been tightly linked to transcribed chro-
matin. No ‘‘reader’’ protein for this modification is known, but it
has been demonstrated that DOT1L activity is essential for sur-
vival of MLL fusion-transformed cells (Bernt et al., 2011; Chang
et al., 2010) and more generally for transcription of the clustered
HOX-homeobox genes. Preclinical studies with DOT1L inhibitors
for treatment of MLL have been promising, and the substances
are in clinical trials (Stein and Tallman, 2015).
A few major target genes of MLL fusion proteins with impor-
tance for transformation have been reported. Among these,
HOX-homeobox genes (mainly HOXA9) and the gene for their
protein interaction partner MEIS1 have been best characterized
(Zeisig et al., 2004). However, it is clear that HOX genes are not
the sole drivers of MLL, mandating the search for additional
genes under control of MLL fusion proteins.
Here we report a strategy that identifies primary target genes
of a conditionally transforming MLL-ENL protein that was
created by insertion of a fusion of human ENL cDNA linked to
a tamoxifen-inducible estrogen receptor into the mouse Mll lo-
cus (henceforth abbreviated MLL-ENL) (Takacova et al., 2012).
By nascent RNA sequencing (RNA-seq), in combination with
chromatin immunoprecipitation (ChIP) for MLL-ENL binding
and the co-occurring chromatin/RNA Pol II modifications, it
was possible to identify a comprehensive list of MLL-ENL tar-
gets. These are distributed across two distinct families, eachcommons.org/licenses/by/4.0/).
Figure 1. Physiological Characterization of
the Transformed-Normal Transition
(A) Experimental setup. MLL-ENL-ER-transformed
cells (Meer) can be generated in large quantities
after activation of the MLL fusion by tamoxifen,
allowing analysis of transcription rates and chro-
matin structure to monitor the kinetics of the
physiological transition from a transformed to a
normal state.
(B) Nascent RNA-seq. Transcription rates were
determined by sequencing of purified nascent
transcripts. At specific time points, cells were
labeled for 1 hr with 4-thiouridine, which incorpo-
rated reactive sulfur side chains into newly syn-
thesized RNA. These were used for reversible
biotinylation and selective purification of nascent
RNA, with subsequent sequencing using next-
generation sequencing techniques.
(C) Physiological characterization of cellular
reversion. Upper left panel: proliferation of Meer
cells after withdrawal of tamoxifen. Averages and
SDs are given for a culture triplicate counted by the
trypan blue exclusion method. Upper right panel:
cell-cycle distribution ofMeer cells. Permeabilized
cells were stained with propidium iodide and
separated into G1/S/G2-M, as well as sub-G1
populations by FACS. Lower panel: self-renewing
cell frequency as determined by CFC numbers in a
limiting dilution experiment.Meer cells were grown
for various periods in the absence of TAM, and
samples were plated as octuplicates in 24-well
plates. Upon serial log2 dilution, CFC frequencies
were calculated from the highest dilution that still
yielded replicating cells in the respective wells.
Averages and SDs of dilution steps are given. The
dotted lines mark 25% and 2.5% self-renewing
frequency.
(D) Morphological aspect of differentiating Meer
cells, May-Gr€unwald-Giemsa stain. Meer cells in
the presence of tamoxifen (0 days) and 6 days, as well as 11 days, after inactivation of MLL-ENL-ER are depicted. m, mitotic figure; ma, macrophage;
gr, granulocyte; ap, apoptotic cell. The lower panel shows a macrophage engulfing an apoptotic granulocyte. The phagocytosed nuclear material of the
granulocyte is visible within the cytoplasm of the macrophage. Pictures were taken at room temperature with a Nikon Digital Sight DS-Fi1 electronic camera
attached to a Zeiss Axioskop with a Zeiss Neofluar 100x/1.25 oil objective and processed with CorelDraw software without image enhancements.characterized by specific biological function, a different chro-
matin environment, and differential sensitivity toward pharmaco-
logical intervention.
RESULTS
Physiological Consequences of MLL-ENL Expression
To follow the transcriptional changes induced by MLL-ENL, we
chose to investigate primary MLL-ENL cells (Takacova et al.,
2012). This ensures expression of the oncogene at physiological
levels and avoids the integration effects that may occur after
retroviral gene transfer. Because leukemia-initiating cells are
rare and poorly characterized, we took an inverse strategy to
examine the processes necessary for maintenance of transfor-
mation (Figure 1A). Large amounts of primary cells immortalized
by MLL-ENL (Meer cells) can be derived in vitro from c-Kit-pos-
itive bone marrow precursors by induction of the oncogene with
tamoxifen. As previously shown (Zeisig et al., 2004), transforma-
tion is fully reversible after removal of the inductor. Because atranscription factor primarily affects transcription rates and it
takes considerable time for a change in transcript production
to show up as an alteration in the steady-state RNA pool, we
decided to determine actual transcription rates by nascent
RNA-seq (Figure 1B). The addition of 4-thiouridine labels newly
synthesized transcripts and allows for specific purification of
nascent RNA by thiol-selective biotinylation and streptavidin
chromatography. Quantification of these transcripts can be
achieved by next-generation sequencing.
Because genetic decisions precede any phenotypical mani-
festation, we recorded the physiological response of Meer cells
after loss of the transforming input to determine the optimal sam-
pling times for the genomic analysis (Figure 1C). Following with-
drawal of tamoxifen, increasing G1 phase arrest was detected at
3 days, with cells stopping proliferation after 7 days. Apoptosis
did not set in until late in the process, with significant sub-G1
populations appearing around 10 days after MLL-ENL inactiva-
tion. The first apparent physiological reaction to a loss of the
transforming driver was a reduction in self-renewal capacity,Cell Reports 15, 310–322, April 12, 2016 311
Figure 2. Transcriptional Profiling of Cellular
Differentiation by Global Nascent RNA-Seq
(A) Example transcript mapping of nascent RNA.
The plot shows reads aligning to the region of
Meis1, a known MLL-ENL target gene. Individual
sample tracks are IGV visualizations of mapping
density at various time points, as indicated. In
contrast to sequencing cytoplasmic RNA, nascent
RNA maps extensively to non-coding regions,
because it contains all possible transcription and
splicing intermediates. cDNA for sequencing was
obtained by random priming.
(B) Verification of nascent RNA quantitation.
Nascent RNA quantification results were obtained
as RPKM values were compared to classical
qPCR-based methods (qPCR), as well as on an
independent biological replicate with Meer cells
derived from a different animal (qPCR repl.). Rela-
tive expression values are plotted against sampling
time for two known MLL-ENL targets (Meis1 and
Hoxa9). The qPCR data points represent averages
and SDs of PCR triplicates.
(C) Proliferation- and differentiation-associated
gene signatures. Left panel: log2-fold changes in
relative gene expression were calculated from
RPKM values for a group of proliferation-associ-
ated genes, reflecting constant proliferation rates
within 72 hr of inactivation of MLL-ENL. Right
panel: in contrast to proliferation, differentiation
markers Gr-1 (Ly6g) and Mac1 (Itgam), as well as
the precursor or stem cell-specific transcript for
Cd34, show characteristic changes after 24 hr.
(D) GSEA of whole genome transcript data. RPKM
values obtained at 0 hr (+TAM, MLL-ENL ‘‘on’’) and
72 hr after inactivation of MLL-ENL (MLL-ENL
‘‘off’’) were fed into the GSEA and compared to
stored profiles in the MSigDB. The three best
scoring matches are shown.
See also Figure S1.as determined by colony-forming assays. Cultivation of Meer
cells for 48 hr without tamoxifen was sufficient to reduce the
colony-forming cell (CFC) frequency from approximately 30%
to below 10%. Microscopically, Meer cells were highly mitotic
myeloblasts, and upon tamoxifen depletion, they developed
into fully mature granulocytes and macrophages within
6–7 days (Figure 1D). Macrophages were phagocytosis compe-
tent and consumed the remnants of short-lived granulocytes
during culture.
The Transcriptional Program Set by MLL-ENL
Next, we determined global transcription rates by next-genera-
tion sequencing of nascent RNA in transformed cells (active312 Cell Reports 15, 310–322, April 12, 2016MLL-ENL = 0-hr value) and during a time
course at 8, 16, 24, 48, and 72 hr after
tamoxifen was washed out. Next-genera-
tion sequencing identified a total of 13,718
transcripts (Table S1) in Meer cells.
Because nascent RNA contains partial
and unspliced RNA, reads were mapped
across the whole primary transcript, withmany hits in intronic sequences (Figure 2A). To confirm the utility
of nascent RNA-derived RPKM (reads per kilobase of transcript
per million readsmapped) values for comparison of transcription
rates across different time points, we quantified nascent tran-
scripts of five known MLL-ENL target genes and of Gr-1
(Ly6g), a differentiationmarker, by conventional qPCR in two bio-
logical replicates derived from different animals (Figure 2B; Fig-
ure S1A). Comparison demonstrated excellent congruency,
corroborating RPKM values as valid scores for transcript abun-
dance. It has been reported that tamoxifen affects gene expres-
sion in hematopoietic stem cells by binding to the endogenous
estrogen receptor (Esr1; Sa´nchez-Aguilera et al., 2014). There-
fore, we tested for potential interference by this substance in
MLL-ENL-transformed cells. For this purpose, primary hemato-
poietic precursor cells were transformed with a constitutive
version of MLL-ENL. Nascent RNA was isolated from these cells
grown in the presence or absence of tamoxifen. The qPCR-
based quantification of several MLL-ENL target genes, as well
as of Myc and c-Kit, two genes allegedly under the control of
tamoxifen in hematopoietic stem cells, did not reveal any major
influence of tamoxifen on their transcription (Figure S1B).
RNA synthesis rates of proliferation-associated genes did not
vary appreciably within 72 hr. In contrast, transcripts of several
genes associated with differentiation changed 24 hr after inacti-
vation of MLL-ENL, indicating that initiation of differentiation pre-
cedes proliferation arrest (Figure 2C).
An unbiased search for gene expression patterns by gene set
enrichment analysis (GSEA) was performed with the RPKM
values obtained at 0 and 72 hr (Figure 2D). Comparison with
the Molecular Signatures Database (MSigDB; http://software.
broadinstitute.org/gsea/msigdb) datasets revealed an excellent
match (false discovery rate = 0, enrichment scores > 2.2) with
a Myc/ribosomal biosynthesis signature in the MLL-ENL ‘‘on’’
state and, as expected, an upregulation of myeloid-specific
genes after inactivation of the oncogene.
Identification of Two Classes of MLL-ENL Target Genes
To identify direct MLL-ENL target genes, ChIP experiments were
performed for all samples using an antibody recognizing the es-
trogen ligand binding domain fused to MLL-ENL. Binding peaks
were automatically identified by magnetically activated cell sort-
ing (MACS) and by manual screening. All potential binding sites
for MLL-ENL in the 0-hr sample were re-examined if they disap-
peared at later time points. As MLL-ENL leaves the locus in the
absence of tamoxifen (Milne et al., 2005), this behavior can be
used as an internal control to discriminate true MLL-ENL sites
from false positives. This procedure identified 165 genes as
potentially regulated by MLL-ENL (Table S2). Based on the loca-
tion of MLL-ENL binding, these targets clearly could be sepa-
rated into two classes (Figure 3A). MLL-ENL was either bound
at the transcription start site (TSS) for the majority (121/165) of
targets (Figure 3A, left panel) or detectable approximately 1- to
2-kb downstream of the regular transcription end site (TES) for
a further 44 genes (Figure 3A, middle panel). According to this
distribution, the genes were designated ME5 and ME3, respec-
tively. Peaks mapped exclusively close to transcripts, and all
could be clearly assigned to one or to two genes if the MLL-
ENL binding site was located between two closely spaced
transcripts. There were no orphan peaks localizing to distal en-
hancers or other remote control elements. Occasionally, a varia-
tion of the typical ME5 pattern (Figure 3B, example Meis1)
occurred, with MLL-ENL bound at positions downstream of the
annotated TSS potentially, highlighting alternative start positions
(Figure 3B, example Chd9). Within the HoxA and HoxB loci (Fig-
ure 3B, example HoxA locus) and for a few short genes, MLL-
ENL occupancy was not restricted to a defined peak but
extended across and beyond the transcribed region. Still, in all
of these cases, the majority of MLL-ENL presence was well
within the annotated transcripts, flagging these targets as mem-
bers of the ME5 group. Next to a number of genes not yet
associated with transformation by MLL fusion proteins, theME5 family contained all classical genes known to be under con-
trol of MLL-ENL, such as HoxA and HoxB cluster genes, Meis1,
and Pbx3. In addition, genes previously associated with MLL
fusion-dependent transformation, such as Cdk6, Jmjd1c,
Lmo2,Mecom, and Eya1, belonged to the ME5 group. However,
the ME3 family was dominated by genes with a function in RNA
biology (e.g., ribosomal biosynthesis, splicing, and small nucle-
olar RNA [snoRNA] host genes), and it contained the oncogene
Myc. Gene ontology analysis (http://amigo.geneontology.org/
amigo) confirmed this functional dichotomy (Figure 3C), with
DNA-binding proteins significantly enriched with the ME5 group
(p = 8.96 3 109) and RNA interacting factors prevailing within
the ME3 family (p = 3.36 3 1011).
To obtain independent evidence for this dichotomous distri-
bution, we analyzed various ChIP datasets previously gener-
ated from MLL-transformed cells (Figures S2 and S3). Guenther
et al. (2008) recorded chromatin immunoprecipitation se-
quencing (ChIP-seq) data with an MLL-N antibody, probing
the distribution of wild-type (WT) MLL and MLL fusion proteins
in the human t(4;11) leukemia line SEM. These data supported
our findings, because WT-MLL or MLL fusion binding was de-
tected around the TSS for ME5 genes, whereas ME3 genes
presented with an additional peak after the transcript end (Fig-
ure S2). Evidence for the presence of ME3 genes was also
found in the dataset of Bernt et al. (2011), who used murine
hematopoietic cells retrovirally transduced by a biotinylated
MLL-AF9 followed by streptavidin precipitation (Figure S3A).
Homologous MLL-AF9 peaks could be identified for individual
ME3 genes, and MLL-AF9 binding at the 30 end of ME3 genes
was discernible in a composite analysis, despite the low signal-
to-noise ratio of the biotin data. Finally, we controlled for cross-
reaction of the antibodies with Esr1 by an analogous ChIP-seq
experiment done with primary cells transformed by Hoxa9 (Fig-
ure S3B). MLL-ENL- and Hoxa9-transformed cells are arrested
at a similar stage in myeloid development, and they contain
similar amounts of Esr1 RNA (data not shown). ME3 peaks ap-
peared exclusively in Meer cells, indicating that these peaks do
not correspond to cross-reactive ER binding sites.
ME5 and ME3 Genes Are Distinguished by Their
Chromatin Signatures
To get deeper insight into the transactivation mechanisms that
drive MLL-ENL target expression, further ChIP-seq experi-
ments were performed. The fusion partner ENL recruits the his-
tone methyltransferase DOT1L and the RNA Pol II C-terminal
domain (CTD) kinase P-TEFb. To measure the output of these
two enzymatic activities, the global distribution of H3K79 dime-
thylation and of serine-2-phosphorylated RNA Pol II (RNA Pol
II-Ser2P) was determined. In addition, the presence of H3K4
methylation as a marker for active chromatin was recorded.
Finally, total RNA Pol II density as an additional gauge for tran-
scriptional activity was measured 0 and 72 hr after MLL-ENL
inactivation (Figure 4A, typical examples, and Figure 4B, com-
posite plots). These studies corroborated the distinction be-
tween ME5 and ME3 genes. Although ME5 and ME3 genes
showed a comparable amplitude of regulation (Figure 4B,
upper panel, left versus right), their response pattern with
respect to the associated histone and RNA Pol II modificationsCell Reports 15, 310–322, April 12, 2016 313
Figure 3. Identification of Two Classes of
MLL-ENL Target Genes
(A) Overlay plots representing the overall MLL-ENL
occupancy of all identified ME5 (n = 121) and ME3
(n = 44) genes, as well as a selection of genes
that changed expression significantly throughout
the time course without MLL-ENL involvement
(n = 30). The sampling time is encoded by colors,
with hues ranging from blue (0 hr) to red (72 hr), as
indicated in the legend.
(B) Example plots of MLL-ENL binding profiles as
determined by ChIP. The kinetics of MLL-ENL
binding during differentiation is drawn as a heat-
map, with each line corresponding to a single time
point (time in hours) or to the negative control
(+TAM sample precipitated with unspecific IgG as
control). MLL-ENL binding patterns fell into two
major clades. ME5 genes showed binding around
the TSS (example Meis1), concentrated around
potential internal start sites (Chd9), or distributed
across the complete transcribed region (Hox
cluster). Yet in these cases, most binding was
situated upstream of the TES. ME3 genes
(example Hspa8) bound MLL-ENL approximately
1- to 2-kb downstream of the TES.
(C) Gene ontology analysis ofME5 andME3 genes.
Gene ontology descriptions of all ME5 and ME3
genes were probed with the AmiGO tool, and the
two highest returning results for each group are
listed.
See also Figures S2 and S3.was different. For ME5 genes, H3K79 dimethylation (Figure 4B,
second panel, left), as an indicator for DOT1L activity, was
proportional to transcriptional output. RNA Pol II-Ser2P distri-
bution (Figure 4B, third panel, left) suggested pausing for
ME5 genes, with two major pause sites present within the first
third of the transcription unit. Further accumulation of RNA
Pol II-Ser2P occurred immediately after the TES. Total amounts
of RNA Pol II-Ser2P across the whole transcription unit were
largely constant throughout the time course. However, com-
paring 0- and 72-hr samples, the overall distribution changed
to more paused RNA Pol II-Ser2P at the 50 end at 72 hr (Fig-
ure 4B, third panel, left: blue and red lines). In summary, these314 Cell Reports 15, 310–322, April 12, 2016observations are consistent with a major
role for DOT1L in the regulation of ME5
genes.
In contrast, transcription rate was not
correlated with H3K79me2 for ME3 tran-
scripts (Figure 4B, second panel, right),
and little evidence for pausing could be
seen in the ME3 group (Figure 4B, third
panel, right). Instead, a massive RNA
Pol II-Ser2P peak accumulated beyond
the termination site of ME3 transcripts at
levels about ten times higher than those
observed for ME5 genes. The amount of
RNA Pol II-Ser2P located at these sites
correlated directly with transcriptional
output. Overall, this pattern argued for apredominant role of P-TEFb as the principal determinant of
ME3 transcription rates. H3K4me2/3 distribution showed minor
differences for each gene family, with most of this modification
either localized immediately upstream or downstream of the
TSS for ME5 and ME3 genes, respectively (Figure 4B, bottom
panels). In both families, the kinetics of H3K4me2/3 deposition
was moderately proportional to transcriptional output, except
for a temporary surge between 8 and 24 hr that was not generally
reflected in transcription rates.
As control, 30 genes with expression levels and regulatory
amplitudes similar to MLL-ENL targets but with no evidence of
MLL-ENL binding were examined for the same chromatin marks
Figure 4. Different Chromatin Environments Characterize ME5 and ME3 Genes
(A) Transcription-related chromatin landscape of ME5 and ME3 genes. Heatmaps detail the chromatin patterns surrounding MLL-ENL target genes Meis1 and
Hspa8 as examples of typical ME5 andME3 genes, respectively. Each line corresponds to an individual time point, as indicated on the right. Heatmaps represent,
from top to down, MLL-ENL occupancy, H3K79 dimethylation resulting from DOT1L action, distribution of RNA Pol II-Ser2P as a surrogate parameter for P-TEFb
activity, H3K4 dimethylation or trimethylation as a general marker of transcriptionally active chromatin, and finally the presence of total RNA Pol II across the
transcription unit. For total RNA Pol II, only 0- and 72-hr values were recorded.
(B) Overlay plots integrating transcription and chromatin parameters for ME5 genes (left column) and ME3 genes (right column). Only genes that showed a
significant response in transcription rate within 72 hr of inactivation of MLL-ENL were included (40% top-changing genes, n = 38 for ME5 and n = 28 for ME3).
Plots represent, from top to down, average relative transcription rates, H3K79 dimethylation, RNA Pol II-Ser2P, and H3K4 dimethylation or trimethylation. Plot
lines are color coded for individual time points, as indicated in the legend, ranging from blue (0 hr) to red (72 hr).
(C) Control plots, as in (B), compiled for 30 genes with expression changes comparable to MLL-ENL target genes but without detectable MLL-ENL involvement.
Genes are listed in Table S2.
(legend continued on next page)
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(Figure 4C). Although H3K79me2 was present on these tran-
scriptional units, it did not change with transcription rates. RNA
Pol II-Ser2P accumulated at the end of the transcribed region
in a manner similar to ME3 genes but at levels more than
10-fold lower and with little correlation to overall RNA produc-
tion. H3K4me2/3 followed the canonical pattern, with a predom-
inance at the TSS and a smaller presence beyond the TES.
The unusual accumulation of transcription-competent RNA
Pol II-Ser2P downstream of the TES of ME3 genes was consis-
tently associated with a small but clearly detectable peak of
RNA transcripts that was generally absent in theME5 group (Fig-
ure 4D; Figure S4A). To examine whether this was simply
readthrough, strand-specific primers were designed to create
directionally primed cDNA. A qPCR analysis detected small
but measurable quantities of bidirectional transcripts covering
the respective region. The expression of these ME3-associated
transcripts followed closely the transcriptional kinetics of their
cognate upstream genes (Figure 4E; Figure S4A). To confirm
that the high levels of RNA Pol II-Ser2P at the 30 end of ME3
genes are the product of active P-TEFb, inhibitor experiments
were performed. Meer cells were treated for 16 hr with 150 nM
JQ1, a substance that blocks chromatin binding of Brd4, a
necessary co-factor for optimal P-TEFb activity (Itzen et al.,
2014). ChIP followed by qPCR for a selection of ME3 genes
showed a significant reduction in RNA Pol II-Ser2P in the pres-
ence of JQ1 (Figure 4F). These results were supported by
ChIP-seq data recorded previously by Roe et al. (2015) in MLL-
AF9-transformed cells (Figure S4B). In addition to a common
broad distribution at the 50 TSS, Brd4 was detected after the
TES exclusively for ME3 but not for ME5 genes. In contrast to
the 50 Brd4 peak that was accompanied by extensive H3K27
acetylation, the 30 peak was devoid of this enhancer mark.
Evaluation of MLL-ENL Target Genes for Biological
Significance
As anticipated, not all genes bound by MLL-ENL were under
transcriptional control of this fusion. A continuous spectrum of
regulatory amplitudes was observed, reflecting the individual
dependence of the respective target on DOT1L/P-TEFb
(Figure 5A). MLL-ENL shared 40% of all targets with the related
fusions MLL-AF9 (Bernt et al., 2011) and MLL-AF4 (Figure 5B;
Wilkinson et al., 2013). We used a test set of ten genes with a
confirmed role in MLL-mediated leukemia (Jmjd1c, Cdk6,
Lmo2, Mef2c, Mecom, Eya, Hoxa9, Hoxa7, Meis1, and Pbx3)
to evaluate whether these confirmed drivers of hematopoietic
transformation were characterized by a special regulatory dy-
namics that would allow prioritizing of targets with unknown
function according to their biological significance. When plotted(D) Special transcript organization at the 30 end ofME3 genes. The transcript map s
ME3 gene (Hspa8). A peak of transcripts co-localizing with the binding ofMLL-ENL
with primers covering the peak area, as schematically indicated.
(E) Strand-specific quantification of ME3-associated transcripts. The graph depic
anti-sense with regard to theHspa8 parental gene. Expression wasmonitored in n
overlaid with the abundance of the overall Hspa8 transcript, as determined from
(F) Effect of JQ1 treatment on RNA Pol II-Ser2P accumulation at the 30 end of ME
essential P-TEFb compound Brd4. A ChIP specific for RNAPol II-Ser2P was perfo
primers localizing at the 30 binding site for MLL-ENL/RNA Pol II-Ser2P, as previo
See also Figure S4.
316 Cell Reports 15, 310–322, April 12, 2016against time, these test genes were clearly among those with the
largest and earliest changes in transcription rate (Figure 5C).
Next, we chose a query set of 11 genes (Sos2, Elf1, Tcf4,
Hnrnpa1, Ptbp1, Ncl1, Calr, Hspa8, Sox4, Rnf220, and Nkx2.3)
with transcriptional dynamics in a similar range (Figure 5D).
Although some of these were known to be mutated in hemato-
logical malignancies, none had an identified role in MLL fusion-
induced disease.
To test the contribution of these genes toward maintenance of
cellular transformation, Meer cells were transduced either with
an empty vector as control or with a single target gene (Fig-
ure 5E). This allowed testing of the influence of an isolated
gene on transformation-relevant parameters in a cellular envi-
ronment after inactivation of MLL-ENL and therefore downregu-
lation of all other targets (Figure 6A, experimental scheme). Five
genes tested (Sos2, Tcf4, Elf1, Nkx2.3, and Rnf220) had a signif-
icant influence on proliferation (Figure 6B). Differentiation was
affected by overexpression of Sox4. The continued presence
of Sox4 prevented the downregulation of surface c-Kit expres-
sion during maturation but had no effect on Gr-1 levels. Nkx2.3
retarded differentiation in general, keeping cells in a proliferative
state for extended times (Figures 6C and 6D). This was also seen
in CFC or replating assays, in which overexpression of Nkx2.3 in
primary hematopoietic stem and precursor cells (HSPCs) was
sufficient to induce colony-forming capacity, reaching about
30% of the activity recorded with Hoxa9 (Figure 6E). Four genes
had anti-apoptotic activity when assaying cell death in response
to 250 nM doxorubicin, a commonly used chemotherapeutic
agent in acute myeloid leukemia (AML): Tcf4, Elf1, Sos2, and
Ncl reduced apoptotic cell numbers moderately but significantly
(Figure 6F). Finally, we tested the consequences of an overex-
pression of a combination of Ptbp1 andHnrnpa1, because these
two genes had been shown to influence alternative splicing of
pyruvate kinase (He et al., 2014). In breast cancer, PTBP1 is
necessary to adapt the cells to aerobic glycolysis as a prerequi-
site for malignant growth, because carbon atoms need to be
spared for the synthesis of new cellular material instead of being
converted to CO2 during oxidative phosphorylation. Alternative
splicing of pyruvate kinase is amajor control point for this switch.
InMeer cells, overexpression of Ptbp1 and Hnrnpa1 favored the
production of the glycolytic Pkm2 isoform (Figure 6G). In sum-
mary, this screening confirmed a function in transformation-rele-
vant processes for 9 of the 11 genes tested.
ME5 and ME3 Genes Respond Differentially to
Pharmacological Inhibition
The high levels of H3K79 methylation accompanying transcrip-
tion of ME5 genes suggested a prevailing function of DOT1Lhows RNA reads in the vicinity of the 30 end of a typical ME5 gene (Meis1) and a
and RNAPol II-Ser2P was probed for directionality by strand-specific priming,
ts a qPCR-based and strand-specific detection of transcripts either in sense or
ascent RNA samples at different time points. For comparison, qPCR values are
RPKM values.
3 genes.Meer cells were treated for 16 hr with 150 nM JQ1, an inhibitor of the
rmed and quantitated by qPCR for a representative selection ofME3 geneswith
usly determined.
Figure 5. SelectingMLL-ENL Target Genes for Biological Relevance
(A) Expression heatmap of all MLL-ENL target genes. Lines represent indi-
vidual genes, with columns corresponding to sample times. Relative changes
were log2 transformed and colored according to the scale given. ME5 genes
are in black font; ME3 genes are in red. Yellow filling highlights genes that are
shared targets among MLL-ENL (this study), MLL-AF9 (Bernt et al., 2011), and
MLL-AF4 (Wilkinson et al., 2013).
(B) Venn diagram showing the relationship of MLL-ENL targets and those of
MLL-AF9 and MLL-AF4, as in (A).
(C) The transcriptional dynamics of genes with a known role in MLL-ENL-
induced leukemia. The relative transcription rates of genes with a previouslyfor their activation. In contrast, ME3 genes appeared to rely more
on P-TEFb activity. Pharmacological substances have been
developed that specifically target these two mechanisms.
EPZ5676 blocks DOT1L activity by competing for binding of
the methyl-donor S-adenosylmethionine (Basavapathruni et al.,
2014). JQ1 perturbs P-TEFb activity by competitively inhibiting
the bromodomain of Brd4 (Filippakopoulos et al., 2010), a factor
that tethers P-TEFb to chromatin (Kanno et al., 2014) and in-
creases its catalytic activity (Itzen et al., 2014). To examine the
influence of these substances on transcriptional regulation,
Meer cells, the human t(4;11) leukemia line SEM, and as a non-
MLL control, REH cells were treated with 150 nM JQ1 (Meer)
or 300 nM JQ1 (SEM and REH) for 16 hr or with 5 mM EPZ5676
(all lines) for 5 days. Because there is no known H3K79 demethy-
lase, it takes several days after incapacitation of DOT1L for the
remaining methylation to be diluted by cell proliferation and
before effects on transcription become visible (Daigle et al.,
2013). Transcriptional rates for five ME5 and five ME3 genes
were determined by qPCR-based quantification of nascent
RNA (Figure 7A). These experiments validated the dichotomous
nature of MLL-ENL target genes. InMeer, JQ1 treatment had no
or only small effects on ME5 genes, while transcription of their
ME3 counterparts was reduced to 10%–40% of the control
levels. EPZ5676 inhibited preferentially ME5 genes, with some
cross-talk to ME3 genes after prolonged exposure time. SEM
cells that are more resistant to EPZ (Daigle et al., 2013) showed
a comparable selectivity of JQ1 treatment for ME3 genes and a
weaker but still observable effect of EPZ5676 on ME5 genes.
EPZ5676 and JQ1 treatment of REH cells did not induce major
effects, with the exception of Myc and Hspa8, which could be
repressed by JQ1.
Because JQ1 and EPZ5676 affected separate subgroups of
MLL-ENL targets, we tested the effect of a combination treat-
ment. Half maximal inhibitory concentration (IC50) values for
EPZ5676 were determined in the presence of varying concentra-
tions of JQ1 (Figure 7B). For this purpose, cells were cultivated in
various concentrations of EPZ5676 for 6 days before increasing
amounts of JQ1 were added to the samples for a further 3 days.
Proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) test. The addition of 125 nM
JQ1 increased sensitivity of Meer cells toward EPZ5676 about
5-fold. The effect in SEM cells was smaller but still significant.
Although REH does not contain anMLL fusion, a minor response
of REH toward EPZ5676 could be seen, as previously noted
(Daigle et al., 2013). This reaction, however, did not respond
further to JQ1 treatment. These results were not simply due to
a different sensitivity toward JQ1. IC50 values for JQ1 wererecognized function in MLL-ENL-mediated transformation are highlighted and
plotted against a background of all MLL-ENL targets, demonstrating their
special dynamics.
(D) Transcriptional profile of MLL-ENL targets with unknown function chosen
as a test set for functional experiments plotted as in (A). ME3 genes are labeled
in red.
(E) Western blot detection of test proteins. Full-length cDNAs of the test set
genes were cloned into pMSCV retroviral vectors encoding an N-terminal
FLAG tag, except Calr, which was tagged C-terminally. Cell extracts from viral
packaging cells were probed for protein expression by a FLAG-specific
immunoblot. ME3 genes are labeled in red.
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Figure 6. Screening MLL-ENL Target Genes
for Biological Function
(A) Experimental setup. Meer cells were trans-
ducedwith a single test gene (T) or as control with a
vector (V) only. After antibiotic selection in the
presence of tamoxifen to keep MLL-ENL ‘‘on,’’ the
cells were cultivated for 72 hr in the absence of
inducer. This leads to a downregulation of all
endogenous MLL-ENL targets, while the trans-
duced test gene is constitutively expressed, al-
lowing examination of its biological function in a
primary cell background.
(B) Effect of individual test genes on cellular
proliferation. Proliferation of test and control
cells was recorded by a standard MTT assay.
To uncover a potential influence of cytokine
stimulation, all cells were incubated in a
dilution series of different cytokine concentrations
(1x = 50 ng/ml SCF, 10 ng/ml IL-3, IL-6, and
GM-CSF). Averages and SDs are given for
absolute optical density (550 nm) values. Gene
and protein names in red belong to the ME3
group.
(C) Expression of the precursor marker c-Kit
on the surface of differentiating test cells. Cell
lines were differentiated in the absence of
tamoxifen, and surface c-Kit was determined by
FACS.
(D) Kinetics of Gr-1 expression during differentia-
tion, determined as in (C).
(E) Replating or CFC assay for Nkx2.3. Primary
bone marrow cells were transduced withNkx2.3 or
Hoxa9 encoding retroviruses or with an empty
vector as a negative control. Cells were cultivated
in methylcellulose medium and replated two times.
Averages and SDs of colonies obtained after two
rounds of replating done in triplicate are depicted.
An example of stained third-round colonies is
given in the right panel.
(F) Influence of test genes on apoptosis. Test cell
lines were incubated for 16 hr in medium supple-
mented with 250 nM doxorubicin. Apoptotic re-
sponses were detected by annexin V-FITC and
propidium-iodide staining coupled to FACS
enumeration. The average values and SDs of
triplicate experiments are plotted.
(G) Influence of MLL-ENL target genes on splicing
of pyruvate kinase RNA. Test cells were trans-
duced with a combination of Ptbp1 and Hnrnpa1.
Total RNA was extracted from test and control
cells in the presence of active MLL-ENL (0 hr) and
72 hr after inactivation of the oncogene by with-
drawal of tamoxifen. Differentially spliced pyruvate kinase RNA was quantified by qPCR with primers specific for either isoform. Pkm1 is preferentially expressed
in an aerobic environment, and Pkm2 becomes predominant under glycolytic conditions. Averages and SDs of PCR triplicates are plotted.110, 50, and 80 nM for Meer, SEM, and REH, respectively, sug-
gesting a true cooperation of JQ1 and EPZ5676 in MLL-rear-
ranged cells.
Because both ME5 and ME3 target families contain known
oncogenes, it is conceivable that the activity of either group
may be sufficient to maintain the transformed state. To investi-
gate this possibility, we used a previously described cohort of
MLL patients that showed an unusual and conspicuous absence
ofHOX-gene transcripts and compared it to a co-published con-318 Cell Reports 15, 310–322, April 12, 2016trol group with MLL translocation and elevated HOX expression
(Figure 7C; Table S3; Stam et al., 2010). Because ME3 genes
function prominently in ribosome biogenesis, probe sets with
the keyword ‘‘ribosomal’’ were selected from the array data.
Among the 382 probes fulfilling this criterion, 177 showed a
statistically significant differential expression (two-tailed t test,
p < 0.05) between the two HOX cohorts. Of those, 173 probes
were upregulated in the HOX-low group, but only 4 probes
were upregulated in HOX-high patients. Similarly, of the 28
Figure 7. Pharmacological Consequences
of the MLL-ENL Target Dichotomy
(A) Differential pharmacological sensitivity of ME5
and ME3 genes. Meer, SEM [human t(4;11) line],
and REH cells without MLL translocation were
treated either for 16 hr with 150 nM JQ1 (REH and
SEM cells were more resistant and received
300 mM JQ1), which displaces Brd4 from chro-
matin, or for 5 days with EPZ5676, which blocks
DOT1L enzymatic activity. Transcription rates for
fiveMLL-ENL targets of each class (ME5 andME3,
as indicated) were determined by qPCR of nascent
RNA isolated from treated and control cells.
Because EVI1 was not expressed in the human
cell lines, the ME5 gene HOXA7 was tested
instead. The plot shows averages and SDs of PCR
triplicates.
(B) Cooperation of JQ1 with EPZ5676.Meer, SEM,
and REH cell cultures were preincubated for
6 days with various concentrations of EPZ5676
and then individually subjected to a MTT test
determining the IC50 concentrations for EPZ5676
in the presence of various concentrations of JQ1.
Experiments were done in triplicate, and averages
and SDs are plotted as relative proliferations.
(C) MLL leukemia patients with low HOX expres-
sion show a compensatory upregulation of ME3
genes and genes involved in ribosomal function.
Published array data (Stam et al., 2010) obtained
from MLL samples collected from a patient col-
lective containing individuals with absent HOX
gene expression were used to analyze gene
expression patterns. Probes for genes with the
keyword ‘‘ribosomal’’ were tested by a two-tailed
Student’s t test for significant (p < 0.05) differential
expression between HOX-low and HOX-high pa-
tients. Probes overexpressed in one or the other
group are depicted in a modified Venn diagram
(left panel). A similar analysis was done for those
ME3 genes that have been identified to be under
MLL-ENL control in Meer cells (right panel).
Detailed results can be found in Table S3.ME3 genes that we found to be effectively controlled by
MLL-ENL, 9 showed differential expression in the HOX ‘‘on’’ or
‘‘off’’ patients, with 8 genes significantly overexpressed in the
HOX-low group and only 1 gene significantly overexpressed in
the HOX-high samples. This would be compatible with compen-
satory upregulation of the ME3 branch of MLL fusion targets
upon loss of HOX expression.CeDISCUSSION
Here we report the molecular character-
ization of cellular transformation induced
by an archetypical MLL fusion protein.
Nascent RNA-seq, combined with global
ChIP-seq, revealed two separate classes
of MLL-ENL targets differing in the under-
lyingmechanism of transcriptional activa-
tion, the associated chromatin modifica-
tions, and their biological function.This dichotomy was mirrored by previous biochemical find-
ings. ENL and other frequently occurring MLL fusion partners
have been identified as members of a macromolecular complex
involved in transcriptional elongation. This assembly was termed
EAP and contained both P-TEFb and DOT1L when purified
through precipitation of ENL (Mueller et al., 2007) or the homolog
AF9 (Monroe et al., 2011). Later experiments demonstrated thatll Reports 15, 310–322, April 12, 2016 319
P-TEFb and DOT1L exist in two individual complexes: SEC
(super elongation complex; Lin et al., 2010) and Dot complex
(DotCom) (Mohan et al., 2010), indicating that ENL associates
with both activities separately. This has been corroborated by
interaction studies demonstrating that binding of ENL to
DOT1L or to members of the AFF family is mutually exclusive
(Maethner et al., 2013). Controlled by an intrinsically disordered
region, ENL/AF9 folds in contact with the respective binding
partner, thus excluding other interactions (Leach et al., 2013).
The separation into ME5- or ME3-type targets can be explained
by an interaction with either DOT1L or P-TEFb, respectively. The
differential usage of alternate enzymatic activities may also
explain the observed differences in sensitivity toward inhibitors
that affect activity of either P-TEFb (JQ1) or DOT1L (EPZ5676).
As a caveat, we cannot formally rule out that JQ1-induced
BRD4 inhibition may have affected other transcriptional regula-
tors. It has been shown that BRD4 can activate genes indepen-
dent of P-TEFb by recruiting proteins like NSD3 (Rahman et al.,
2011). BRD4 also has been demonstrated to increase P-TEFb
catalytic activity (Itzen et al., 2014) beyond simply tethering
P-TEFb to chromatin. This may explain how the presence of
BRD4 can regulate P-TEFb even if this kinase complex is already
recruited by an MLL fusion. The distribution of RNA Pol II along-
side the body of ME5 genes is congruent with pausing. Polymer-
ases stop before bottlenecks of transcription that need to be
cleared before efficient readthrough can occur. DOT1L-induced
methylation counteracts SIRT1-mediated deacetylation of his-
tones (Chen et al., 2015), thus keeping chromatin in a permissive
conformation. Because ME3 genes are on average shorter
(17 kb) than those of the ME5 class (100 kb), they may contain
fewer pausing sites, thus relying more on the action of P-TEFb
and less on chromatin modification by DOT1L. It is not entirely
clear how a 30-positioned MLL-ENL may stimulate transcription.
The absence of H3K27 acetylation at the 30 end of ME3 genes
makes the presence of a classical enhancer unlikely. Still, the
RNA Pol II-Ser2P that co-accumulates with MLL-ENL is clearly
transcription competent, as evidenced by the bidirectional tran-
scripts emanating from these peaks. There is precedence that
transcription can keep chromatin open (Dai and Dai, 2012),
and the transcripts starting from the 30 MLL-ENL/RNAPol II bind-
ing sites may be one possibility for such a process. Alternatively,
MLL-ENLmay have traveled with RNA Pol II, accumulating at the
30 end of the ME3 transcription units. In addition, both DOT1L
and P-TEFb activity can be found on non-MLL-controlled tran-
scription units, albeit at lower rates.
The separation of control mechanisms is in line with a func-
tional difference between ME5 and ME3 genes. The latter are
preferentially involved in synthesis, maturation, or assembly of
stable and non-coding RNA. They encode ribosomal proteins,
polymerase I-associated transcription factors, and nucleolar
RNAs, or they are host RNAs for snoRNA, which is important
for modification of rRNA during ribosome biogenesis. Also Myc
belongs to the ME3 family, recalling earlier studies in which
Myc was shown to control differentiation of MLL-ENL-trans-
formed cells (Schreiner et al., 2001). Increasing evidence links
this oncogene with regulation of non-coding RNA, as well as
ribosome production (Campbell andWhite, 2014). Unfortunately,
ribosomes, stable RNA, and RNA polymerase I are under-320 Cell Reports 15, 310–322, April 12, 2016researched topics, partly because most algorithms filter for ribo-
somal-associated transcripts. Interest in this topic reappeared
as it was realized that RNA polymerase I inhibitors have anti-
neoplastic properties and may offer alternative treatment op-
tions (Drygin et al., 2011).
The composition of ME5 genes is more complex. They encode
many transcription factors that provide cellular identity, with
an overall predominance of homeobox proteins. Besides
HoxA and HoxB members, the non-clustered homeobox gene
Nkx2.3 was one of the top-scoring MLL-ENL targets. As previ-
ously shown for most HoxA proteins (Bach et al., 2010), Nkx2.3
expression induced CFC activity in primary hematopoietic pre-
cursor cells. Another prominent feature of the ME5 group was
the occurrence of many genes that have been identified either
in non-MLL-rearranged leukemia or as MLL fusion partners.
The Mecom locus (Evi1), Npm1, Lmo2, Myb, Runx1, Runx2,
Etv6, Aff1, andMllt10 are examples of genes with leukemogenic
involvement, suggesting a universal genetic network driving
myeloid transformation.
Cross-talk exists between ME5 and ME3 genes, for example,
through the ME5 gene Myb that activates the ME3 protagonist
Myc (Pattabiraman and Gonda, 2013). Therefore, inhibition of
one clade of target genes should eventually affect the other,
and vice versa. Still, the combination treatment experiments
imply that targeting both gene families may achieve more effi-
cient cell elimination. This would suggest a potential combina-
tion therapy for treatment of this aggressive leukemia and may
provide an alternative for patients whose disease has become in-
dependent of HOX genes.
EXPERIMENTAL PROCEDURES
Generation of Meer Cells and Cell Culture
For generation of Meer cells, primary hematopoietic precursor cells were iso-
lated from the bone marrow of Meer mice that carry a knockin of an ENL-ER
(mutant ER ligand binding domain) portion into the mouseMll locus (Takacova
et al., 2012). CD117 (c-kit)-positive cells were isolated bymagnetic enrichment
according to the instructions of the manufacturer (Miltenyi) and initially plated
in methocel (MethoCult M3234, STEMCELL) before being expanded in
RPMI1640 supplemented with 10% fetal calf serum. All media contained
50 ng/ml recombinant murine (rm) stem cell factor (SCF); 10 ng/ml rm inter-
leukin (IL) 3, IL-6, and granulocyte macrophage colony stimulating factor
(GM-CSF; Miltenyi); and for activation of the ER, 100 nM 4-hydroxytamoxifen
(TAM, Sigma). Independent batches of Meer cells were grown from different
animals approximately every 3 months to avoid alterations induced by pro-
longed culture. Retroviral transduction was done as outlined in Lavau et al.
(1997). All animal experiments were performed under the oversight of the local
institutional review board (license number TS99/01/Genetik).
Proliferation, Cell Cycle, Limited Dilution, Apoptosis, CFC Assays,
and Inhibitors
Proliferation was determined either by manual counting after staining with try-
pan blue or by a standard MTT assay according to the instructions of the
manufacturer (Promega). Cell-cycle distribution was characterized by propi-
dium-iodide staining and fluorescence-activated cell sorting (FACS) according
to standardmethods. CFCs were enumerated by a limited dilution experiment.
For this purpose, Meer cells were seeded at 1,000 cells per well in a 96-well
plate and serially diluted. CFC numbers were calculated by scoring the
maximum possible dilution that created wells with colony-forming activity.
To assay CFC activity, the cells were replated three times in methocel and
numbers of stained colonies were counted, as previously reported (Lavau
et al., 1997). Apoptosis rates were determined by annexin V-fluorescein
isothiocyanate (FITC) and propidium-iodide staining coupled with FACS using
the corresponding eBioscience detection kit according to the instructions pro-
vided. JQ1 and EPZ5676 were obtained from Selleckchem.
Generation and Purification of Nascent RNA
To determine RNA synthesis rates, newly transcribed RNA was labeled by
addition of 100 mM 4-thiouridine (Sigma) to the cell culture medium. After
1 hr, total RNA was isolated by RNeasy spin column purification according
to the instructions of the manufacturer (QIAGEN). Then, 100 mg of RNA were
biotinylated with 200 mg/ml of EZ-Link HPDP Biotin (Pierce-Thermo) in 1 ml
of 10 mM Tris-HCl (pH 7.4), 1 mM EDTA. Biotinylated nucleic acid was bound
to mMACS streptavidin magnetic beads and washed as recommended by the
manufacturer (Miltenyi). Elution of retained material was done with 100 mM
DTT. After a final purification on RNeasy columns, nascent RNAwas subjected
to standard reverse transcription and qPCR.
ChIP
ChIP was done exactly as described in Milne et al. (2009) with the exception
that protein G-coupled magnetic beads from Cell Signaling Technology
were used. For ChIP of the ER fusion, a two-step protocol was used. After
overnight incubation with anti-ER antibodies, anti-mouse immunoglobulins
(Igs) were added to enhance the signal. Antibodies and concentrations
used were anti-ER (TE111.5D11; Thermo Scientific), 2.5 mg per assay; anti-
mouse IgG or IgM (H+L; Thermo Scientific/Pierce 31198), 2.5 mg per
assay; anti-H3K79 dimethyl (AbCam 3594 polyclonal AB), 2 mg; anti-RNA
Pol II CTD Ser2P (ActiveMotif 61083), 10 mg; anti-total RNA Pol II (ActiveMotif
39097), 2 mg; and anti-H3K4 dimethyl or trimethyl (ActiveMotif 39159 poly-
clonal), 3 ml.
qPCR
qPCR was done with Stratagene SYBR III ultra-fast premix as laid out by the
manufacturer. Primers used are listed in Table S4.
Statistical Methods
For statistical analysis, two-tailed t tests were applied. Significance was
assumed for p < 0.05. Charts depict means and SDs of at least triplicates.
Next-Generation Sequencing and Data Deposition
Nascent RNA samples were commercially sequenced by GATC. In short,
random primed sequencing libraries were generated from RNA samples ac-
cording to standard Illumina procedures and sequenced on HiSeq2000 as
50-bp single-end reads. Three samples weremultiplexed per lane, yielding be-
tween 483 106 and 693 106 reads, of which, on average, 90% could be map-
ped to the reference genome (mm9) using TopHat 2.0.4 and Bowtie 0.12.7.
Transcript abundance in RPKM was calculated with Cufflinks-Cuffdiff 2.0.2.
Binary alignment/map (Bam) files were converted to normalized tiled data files
(Tdfs) with integrated genome viewer (IGV) tools (Broad Institute) and visual-
ized with the IGV browser.
ChIP samples were sequenced with Source BioScience. Reverse cross-
linked and purified DNA was used for library preparation according to Illu-
mina standard procedures, except that no size selection was done. Up
to 15 samples were multiplexed per HiSeq2000 lane, generating between
5 3 106 and 50 3 106 100-bp paired-end reads with generally >80% map-
pable reads. Alignment was done to mm10 with BWA 0.7.5a. Peaks were
called with MACS14. Visualization of normalized Tdfs was again done with
the IGV browser package. In addition, all MLL-ENL peaks were manually
confirmed, and obvious peak finding errors were corrected. Composite plots
were assembled with NGS-plot (Shen et al., 2014) or with CoverageView
1.5.2 (for the data of Guenther et al., 2008), because in this case no raw
data have been submitted and the composite plots were assembled from
the available bigWIG files.
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